Imara presents imr-687 phase 2a open label extension case reports on two patients with sickle cell disease at the 62nd ash annual meeting and exposition

Preliminary data as of august 2020 from ongoing phase 2a o pen l abel e xtension trial s howed increase s in hbf percentage and f-cell s after approximately six months of treatment

ELVN Ratings Summary

ELVN Quant Ranking